Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.53
-0.4%
$4.99
$3.42
$7.20
$254.65M1.751.54 million shs495,179 shs
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$3.23
+15.8%
$2.30
$1.03
$3.35
$647.09M1.442.19 million shs14.88 million shs
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$5.99
+3.5%
$4.82
$1.58
$6.44
$533.13M0.891.38 million shs5.07 million shs
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$2.05
+12.0%
$1.26
$0.66
$3.00
$190.66M2.481.28 million shs2.96 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-0.44%+0.89%-3.21%+2.03%-23.74%
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
+15.77%+23.28%+38.63%+119.73%+101.88%
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
+3.45%+13.02%+15.86%+93.23%+254.44%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
+12.02%+25.77%+60.16%+178.91%-22.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.4356 of 5 stars
0.01.00.00.03.00.80.6
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
3.2105 of 5 stars
3.84.00.00.02.31.70.6
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2.2627 of 5 stars
3.61.00.00.02.51.70.6
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
2.0222 of 5 stars
3.53.00.00.00.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
3.50
Strong Buy$9.00178.64% Upside
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.14
Buy$20.20237.23% Upside
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
3.00
Buy$8.50314.63% Upside

Current Analyst Ratings Breakdown

Latest CRBU, ATYR, ATAI, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Aegis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/2/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $12.00
6/20/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.00
6/4/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
5/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$5.00
5/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/19/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
5/13/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $3.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.03$0.61 per share7.41$7.78 per share0.58
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$310K2,087.41N/AN/A$0.69 per share4.68
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$230K2,317.87N/AN/A$0.83 per share7.22
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$9.99M19.08N/AN/A$2.79 per share0.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1141.1810.30N/A1.32%0.13%0.10%8/6/2025 (Estimated)
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$149.27M-$0.91N/AN/AN/AN/A-102.10%-77.55%8/12/2025 (Estimated)
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$64.02M-$0.81N/AN/AN/AN/A-87.09%-64.77%8/12/2025 (Estimated)
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$149.10M-$1.62N/AN/AN/A-1,490.84%-55.70%-45.35%8/5/2025 (Estimated)

Latest CRBU, ATYR, ATAI, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.13N/AN/AN/AN/AN/A
8/12/2025Q2 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.18N/AN/AN/AN/AN/A
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18N/AN/AN/A$96.83 millionN/A
8/5/2025Q2 2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.40N/AN/AN/AN/AN/A
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/14/2025Q1 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.19-$0.15+$0.04-$0.15N/A$1.56 million
5/8/2025Q1 2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million
5/7/2025Q1 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.19-$0.17+$0.02-$0.17N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
N/AN/AN/AN/AN/A
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/AN/A
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
0.08
4.07
4.07
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
0.01
7.79
7.79
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/A
7.63
7.63

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
28.41%
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
61.72%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
77.51%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
26.80%
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.70%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
8.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.21 million56.21 millionOptionable
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
80200.34 million146.65 millionOptionable
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5389.00 million85.71 millionOptionable
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
10093.00 million85.30 millionOptionable

Recent News About These Companies

CRBU Caribou Biosciences, Inc. - Seeking Alpha
Caribou reduces workforce by 32%, discontinues GALLOP and AMpLify trials

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.53 -0.02 (-0.44%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.54 +0.00 (+0.11%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

atai Life Sciences stock logo

atai Life Sciences NASDAQ:ATAI

$3.23 +0.44 (+15.77%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.32 +0.09 (+2.79%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

aTyr Pharma stock logo

aTyr Pharma NASDAQ:ATYR

$5.99 +0.20 (+3.45%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.16 +0.18 (+2.92%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Caribou Biosciences stock logo

Caribou Biosciences NASDAQ:CRBU

$2.05 +0.22 (+12.02%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.05 0.00 (0.00%)
As of 07/18/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.